Probenecid with Cefazolin (Ancef): Dosing and Use
Probenecid 500 mg orally four times daily should be used with cefazolin 2 grams IV once daily for outpatient treatment of skin and soft tissue infections, and this combination is effective and well-tolerated.
Mechanism and Rationale
Probenecid is a renal tubular blocking agent that inhibits the tubular excretion of beta-lactam antibiotics 1. When combined with cefazolin, it significantly prolongs the antibiotic's half-life and maintains therapeutic serum concentrations throughout a 24-hour dosing interval 2, 3. This pharmacokinetic enhancement allows once-daily dosing of cefazolin while maintaining concentrations above the minimum inhibitory concentration (MIC) for common skin pathogens like Staphylococcus aureus and beta-hemolytic streptococci 3.
Standard Dosing Regimen
For skin and soft tissue infections:
- Cefazolin: 2 grams IV once daily
- Probenecid: 1 gram orally once daily (given concurrently with cefazolin)
This is the most extensively studied regimen 4, 3, 5.
Alternative regimen (for more severe infections or when higher trough levels needed):
- Cefazolin: 2 grams IV twice daily (every 12 hours)
- Probenecid: 500 mg orally four times daily
This twice-daily regimen maintains higher steady-state trough concentrations (approximately 2.67 mg/L) compared to once-daily dosing 2, 6.
Clinical Efficacy
The cefazolin-probenecid combination demonstrates equivalent efficacy to ceftriaxone for moderate-to-severe cellulitis. In a randomized controlled trial, clinical cure occurred in 86% of patients receiving cefazolin-probenecid versus 96% receiving ceftriaxone (not statistically significant, p=0.11) 4. At one-month follow-up, cure rates were maintained at 96% versus 91% respectively 4.
The combination is also non-inferior to oral cephalexin for uncomplicated mild-to-moderate skin infections, with treatment failure rates of 4.2% versus 6.1% at 72 hours 5.
Expanded Indications
Beyond skin infections, emerging evidence supports use for bone and joint infections. In a retrospective study of 69 patients treated with cefazolin 2g IV plus probenecid 1g PO both twice daily, outcomes included 6:
- Treatment completion: 81%
- Resolution of signs/symptoms: 77%
- Treatment failure requiring therapy change: 10%
- Recurrence: 9%
These outcomes appear comparable to standard therapy, though prospective trials are needed 6.
Important Contraindications and Cautions
Do NOT use probenecid with cefazolin in:
- Known renal impairment (creatinine clearance <50 mL/min or GFR <30 mL/min) 7, 1
- History of uric acid kidney stones 7
- Sulfa drug allergy (use with caution) 8
- Pregnancy (use with caution) 8
- Children (insufficient dosing data) 8
The FDA drug label explicitly states: "probenecid is not recommended in conjunction with a penicillin in the presence of known renal impairment" 1. This applies to all beta-lactams including cefazolin.
Adverse Effects
Probenecid-related:
- Nausea (more common than with ceftriaxone alone, p=0.048) 4
- Headache, anorexia, vomiting 8, 1
- Rare but serious: hemolytic anemia, hepatic necrosis, nephritic syndrome 8
- Uric acid stones, renal colic 8
Overall tolerability: Antimicrobial changes due to intolerance occur in approximately 3-6% of patients, similar to other regimens 9.
Monitoring Requirements
- Renal function assessment before initiation 1
- Fluid intake: Liberal hydration recommended to prevent uric acid stone formation 7
- Urine alkalinization may be considered with potassium citrate if history of stones 7
- For prolonged therapy: Monitor for reducing substances in urine (false-positive glucose) 1
Drug Interactions
Critical interactions:
- Salicylates antagonize the uricosuric effect of probenecid 1
- Methotrexate: Probenecid increases plasma concentrations—use with extreme caution 1
- Oral sulfonylureas: May prolong action and increase hypoglycemia risk 1
- NSAIDs: Probenecid increases plasma levels of indomethacin, naproxen, ketoprofen 1
Practical Advantages
This combination offers several benefits over ceftriaxone:
- Cost-effective: Significantly cheaper than ceftriaxone 4, 3
- Antimicrobial stewardship: Avoids unnecessary use of third-generation cephalosporins 4
- Outpatient feasibility: Enables home-based parenteral therapy 4
Special Populations
Hyperfiltration states (eGFR >130 mL/min/1.73m²): Probenecid is particularly useful in patients with augmented renal clearance, including those with sickle cell disease, where it can increase antibiotic trough concentrations by a median of 228% 10.
Higher body weight/FFM: Patients with higher fat-free mass and eGFR may require 6-hourly dosing with probenecid to achieve PK/PD targets 11.